eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1-2/2005
vol. 30
 
Share:
Share:
abstract:

Experimental immunology
Azathioprine-induced severe aplastic anaemia in thiopurine S-methyltransferase deficient patient with Crohn’s disease

Barbara Zdziarska
,
Mateusz Kurzawski
,
Ewa Wierzbicka-Paczos
,
Anna Kozłowska
,
Maria Chosia
,
Andrzej Pawlik
,
Marek Drozdzik

Centr Eur J Immunol 2005; 30 (1-2): 1-3
Online publish date: 2006/07/26
View full text Get citation
 
TPMT is an enzyme that catalyses S-methylation of thiopurine drugs, which activity is genetically determined. TPMT-deficient patients are at risk of toxicity after standard doses of thiopurine drugs. We describe a case of Crohn’s disease diagnosed patient inheriting genetic TPMT deficiency (TPMT*3A/*3A genotype), who developed severe aplastic anaemia, confirmed by biopsy, after 55 days of treatment with AZA at a standard daily dose of 2.5 mg/kg. This case demonstrates the importance of TPMT polymorphism testing in order to prevent myelotoxicity during treatment with thiopurine drugs.
keywords:

Thiopurine S-methyltransferase, azathioprine, Crohn’s disease, aplastic anaemia

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.